Sera Prognostics reports Q4 net loss $9.7M, revenue $65k; positive AVERT PRETERM trial results

SERA PROGNOSTICS, INC.

Q4 2022 net loss $9.7M vs $12.5M in Q4 2021; revenue $65k vs $26k.
Full year 2022 revenue $268k; cash and securities $104.0M at Dec 31, 2022.
AVERT PRETERM trial showed generalizability of PreTRM test-and-treat strategy improving neonatal outcomes.
PRIME study surpassed required 2,800 subject enrollment; interim look analysis expected by year end.
R&D expenses $3.5M in Q4; SG&A $6.9M down from $9.5M due to sales streamlining.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

SERA PROGNOSTICS, INC. reported the fiscal year ended December 31, 2022 results: revenue $268,000.

Period: the fiscal year ended December 31, 2022
Revenue: $268,000
Result: reported results

Exact text from the filing

Total full year 2022 revenue of $268,000 compared to $82,000 for full year 2021.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

SERA PROGNOSTICS, INC. reported the fourth quarter ended December 31, 2022 results: revenue $65,000, net income $9.7 million.

Period: the fourth quarter ended December 31, 2022
Revenue: $65,000
Net income: $9.7 million
Result: reported results

Exact text from the filing

Fourth quarter 2022 revenue of $65,000 compared to $26,000 for the same period of 2021. Total operating expenses were $10.5 million, down from $12.6 million for the fourth quarter of 2021. Research and development expenses for the fourth quarter of 2022 were $3.5 million compared to $3.1 million for the fourth quarter of 2021 due primarily to increased headcount and research activities. Selling, general and administrative expenses for the fourth quarter of 2022 were $6.9 million, down significantly from $9.5 million for the year-ago period due primarily to steps we took during the prior quarter to streamline our sales operations and to better focus our commercial strategy in response to market dynamics, as well as decreased administrative costs resulting from operational efficiencies. Net loss for the fourth quarter of 2022 was $9.7 million compared to $12.5 million for the same quarter a year ago.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

SERA PROGNOSTICS, INC. filing history →

Source: SEC EDGAR

accession 0001534969-23-000028

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.